公开(公告)号：KR101770748B1

公开(公告)日：2017-08-23

申请号：KR1020150158863

申请日：2015-11-12

Applicant: 서울대학교산학협력단

Inventor： 장인진 ,  조주연 ,  지상천

IPC: C12Q1/68

Abstract: 본발명은, 약물에의한간 손상진단을위한바이오마커에관한것으로서, miR-122의서열에상보적인프라이머를포함함으로써아목시실린또는클라불란산에의한간 손상을진단또는예측할수 있는키트및 간손상발생에대한정보제공방법에관한것이다.

Abstract translation: 本发明涉及一种由药物引起的损害诊断肝的生物标志物，的miR-122 uiseo柱互补由包括底漆阿莫西林或克拉维酸可以诊断或预测在试剂盒中的肝损害和肝障 本发明涉及提供关于用户的信息的方法。

公开(公告)号：KR1020170055735A

公开(公告)日：2017-05-22

申请号：KR1020150158863

申请日：2015-11-12

Applicant: 서울대학교산학협력단

Inventor： 장인진 ,  조주연 ,  지상천

IPC: C12Q1/68

Abstract: 본발명은, 약물에의한간 손상진단을위한바이오마커에관한것으로서, miR-122의서열에상보적인프라이머를포함함으로써아목시실린또는클라불란산에의한간 손상을진단또는예측할수 있는키트및 간손상발생에대한정보제공방법에관한것이다.

公开(公告)号：KR1020120029953A

公开(公告)日：2012-03-27

申请号：KR1020100092100

申请日：2010-09-17

Applicant: 서울대학교산학협력단

Inventor： 장인진 ,  조주연 ,  정재용

IPC: C12Q1/68 ,  C12N15/11 ,  G01N33/15 ,  A61K31/135

CPC classification number: C12Q1/6888 ,  A61K31/135 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/15

Abstract: PURPOSE: A polynucleotide for drug metabolism prediction including single nucleotide polymorphism of a nr1i2 gene, a kit and a drug metabolism prediction method using thereof are provided to increase prediction probability and predict metabolic activation of bupropion according to process of rifampin by simple confirmation of genotype. CONSTITUTION: A marker for predicting drug metabolism includes polynucleotide or complement thereof consisting of 8-200 continuous DNA sequences which respectively include 705th,34403rd, and 34823rd DNAs of polynucleotide which is represented by sequence number 1[SEQ ID NO:1]. The drug is bupropion. The drug metabolism is metabolism of the bupropion according to administration of rifampin. In the metabolism of bupropion, the bupropion is converted into hydroxybupropion. A kit for drug metabolism prediction includes a marker for the drug metabolism prediction. The drug metabolism prediction method comprises the following steps: obtaining nucleic acid sample material which includes NR1I2 gene; amplifying the polynucleotide which respectively includes 705th, 34403rd, and 34823rd DNAs of polynucleotide which is represented by sequence number 1; and determining genotype of 705th, 34403rd, and 34823rd DNAs of the polynucleotide which is represented by sequence number among the amplified polynucleotides.

Abstract translation: 目的：提供包括nr1i2基因的单核苷酸多态性，使用该试剂盒和药物代谢预测方法的药物代谢预测多核苷酸，以通过简单确认基因型来增加预防概率，并根据利福平的过程预测安非他酮的代谢活化。 构成：用于预测药物代谢的标记物包括由序列号1 [SEQ ID NO：1]表示的分别包含第7​​05,34403rd和34823rd多核苷酸的DNA的8-200个连续DNA序列组成的多核苷酸或其补体。 药物是安非他酮 根据利福平的施用，药物代谢是安非他酮的代谢。 在安非他酮的代谢中，安非他酮被转化为羟基安非他力。 用于药物代谢预测的试剂盒包括用于药物代谢预测的标记物。 药物代谢预测方法包括以下步骤：获得包含NR1I2基因的核酸样品; 扩增分别包含序列号1表示的多核苷酸的第705,34403和34823个DNA的多核苷酸; 并确定由扩增的多核苷酸中的序列号表示的多核苷酸的第705,34403和34823rd个DNA的基因型。